G
Genespire
Developing efficient gene therapies for people with inherited metabolic diseases and primary immunodeficiencies
About Genespire
Genespire is a preclinical stage biotechnology company based in Milan, Italy, co-founded by Fondazione Telethon and Ospedale San Raffaele. The company specializes in developing transformative gene therapies for individuals affected by genetic diseases with high unmet medical needs. Leveraging decades of experience from the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Genespire focuses on inherited metabolic diseases and primary immunodeficiencies (PIDs). The leadership team and scientific founders bring extensive expertise from renowned institutions and biopharmaceutical organizations, ensuring a deep understanding of biological research, drug discovery, and development. Genespire operates in the biotechnology sector, primarily serving patients with rare genetic disorders. The business model revolves around research and development (R&D) of gene therapies, aiming to bring these therapies to market through clinical trials and regulatory approvals. Revenue generation is anticipated through partnerships, licensing agreements, and eventual commercialization of approved therapies. Keywords: gene therapy, biotechnology, inherited diseases, metabolic disorders, immunodeficiencies, preclinical stage, Milan, R&D, rare diseases, transformative treatments.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Milan, Italy
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 78.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Immune System, Gene Therapy, Spinout, Disease, Metabolism, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Genespire.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Sep 2024 | $51M | $205M | CDP Venture Capital · XGEN Venture · Sofinnova Partners | ↗ |
| SERIES AOther financing | Apr 2020 | $18M | $33M | Sofinnova Partners | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Genespire is 230 monthly website visits, down 59.6% over the last three months. Genespire's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Sofinnova Partners
CDP Venture Capital
XGEN Venture
Other known investors1 additional known investor
San Raffaele Hospital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Genespire on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Genespire’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.